This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

668

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Epilepsy
Interventions
DRUG

Brivaracetam

"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 10 mg and 25 mg~* Route of Administration: Oral"

Trial Locations (100)

Unknown

N01199 1051, Phoenix

N01199 1362, Phoenix

N01199 1374, Tucson

N01199 1050, Little Rock

N01199 1078, Fresno

N01199 1392, Newport Beach

N01199 1087, San Francisco

N01199 1368, San Francisco

N01199 1396, Atlanta

N01199 1385, Augusta

N01199 1356, Chicago

N01199 1388, Springfield

N01199 1375, Wichita

N01199 1364, Lexington

N01199 1380, Louisville

N01199 1052, Paducah

N01199 1083, Ruston

N01199 1373, Baltimore

N01199 1086, Bethesda

N01199 1077, Burlington

N01199 1391, Detroit

N01199 1395, Detroit

N01199 1071, Grand Rapids

N01199 1389, Saint Paul

N01199 1079, Tupelo

N01199 1360, Chesterfield

N01199 1352, St Louis

N01199 1069, Great Falls

N01199 1062, Toms River

N01199 1053, New York

N01199 1365, Rochester

N01199 1366, Cincinnati

N01199 1054, Columbus

N01199 1359, Portland

N01199 1055, Philadelphia

N01199 1059, Philadelphia

N01199 1081, Greenville

N01199 1061, Nashville

N01199 1084, Dallas

N01199 1394, Dallas

N01199 1064, Houston

N01199 1082, Salt Lake City

N01199 1367, Charlottesville

N01199 1393, Richmond

N01199 1376, Seattle

N01199 1369, Milwaukee

N01199 1420, Chatswood

N01199 1430, Randwick

N01199 1423, Adelaide

N01199 1428, Woodville

N01199 1427, Clayton

N01199 1426, Parkville

N01199 1421, West Heidelberg

N01199 1422, Fitzroy

N01199 1028, Campinas

N01199 1325, Curitiba

N01199 1024, Florianópolis

N01199 1150, Florianópolis

N01199 1331, Porto Alegre

N01199 1332, Porto Alegre

N01199 1022, Riberao Preto

N01199 1023, Salvador

N01199 1029, São José do Rio Preto

N01199 1021, São Paulo

N01199 1027, São Paulo

N01199 1030, São Paulo

N01199 1326, São Paulo

N01199 1316, Edmonton

N01199 1312, Greenfield Park

N01199 1311, Montreal

N01199 1314, Montreal

N01199 1313, Québec

N01199 1266, Mumbai

N01199 1045, Bangalore

N01199 1256, Bangalore

N01199 1257, Bangalore

N01199 1261, Bangalore

N01199 1046, Chennai

N01199 1042, Hyderabad

N01199 1253, Hyderabad

N01199 1262, Hyderabad

N01199 1258, Jaipur

N01199 1040, Lucknow

N01199 1250, Lucknow

N01199 1043, Mumbai

N01199 1259, Mumbai

N01199 1265, Parel Mumbai

N01199 1251, Pune

N01199 1264, Pune Maharashtra

N01199 1263, Tirupati

N01199 1412, San Nicholas de Los Garza

N01199 1010, Aguascalientes

N01199 1008, Chihuahua City

N01199 1009, Chihuahua City

N01199 1003, Guadalajara

N01199 1403, Mexico City

N01199 1005, Monterrey

N01199 1007, Monterrey

N01199 1002, San Luis Potosí City

N01199 1001, Zapopan

All Listed Sponsors
lead

UCB PHARMA Inc. (US)

INDUSTRY

NCT00150800 - This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment | Biotech Hunter | Biotech Hunter